May 2, 2024Cancer Research

Abstract PO3-01-02: Real world outcomes of neoadjuvant therapy with Trastuzumab and Pertuzumab associated with carboplatin and docetaxel (TCHP) in HER2+ early breast cancer patients unfit for anthracyclines: a retrospective cohort comparative study

View Full Paper

Ask AI

Bookmark

Authors

RPRicardo PintoUniversidade do Porto RCRita CalistoUniversidade do Porto PRPatrícia RedondoInstituto Português de Oncologia Francisco Gentil

Discussion

Member takes

Implication

Retrospective cohort study reveals TCHP achieves higher pCR rates in HER2+ early breast cancer patients unfit for anthracyclines, suggesting broader use.

Key Points

The TCHP regimen achieved a pathological complete response rate of 65.2%, compared to 46.1% for AC-DHP.
A total of 233 patients used TCHP, while 23 were treated with AC-DHP over a follow-up of 31.1 months.
Analysis employed multivariate logistic regression for effectiveness and gamma general models for cost effectiveness assessment of TCHP versus AC-DHP regimens, revealing cost savings implications overall for TCHP treatments against AC-DHP ones. Overall, cardiac safety in both methods was comparable, with significant LVEF decreases, yet TCHP still exhibited acceptable attributes for real-world adoption.

Cite This Study

Pinto et al. (2024) studied this question.

synapsesocial.com/papers/68e6be8eb6db64358763e440 https://doi.org/10.1158/1538-7445.sabcs23-po3-01-02

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals TCHP achieves higher pCR rates in HER2+ early breast cancer patients unfit for anthracyclines, suggesting broader use.

Abstract PO3-01-02: Real world outcomes of neoadjuvant therapy with Trastuzumab and Pertuzumab associated with carboplatin and docetaxel (TCHP) in HER2+ early breast cancer patients unfit for anthracyclines: a retrospective cohort comparative study

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PO3-01-02: Real world outcomes of neoadjuvant therapy with Trastuzumab and Pertuzumab associated with carboplatin and docetaxel (TCHP) in HER2+ early breast cancer patients unfit for anthracyclines: a retrospective cohort comparative study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider